Effect of a new ultrashort betalytic agent on aconitine-induced arrhythmia.
The anti-arrhythmic effect was tested on the model of aconitine-induced arrhythmia. The experiment was performed in vivo with 31 male Wistar laboratory rats. Group A was first administered aconitine and, after the onset of the first sinus rhythm disorders, the 44Bu compound was administered. Group B was first administered the 44Bu compound and only after that the aconitine. The control group was administered aconitine and saline as a replacement of the tested compound. In group A, there was a decrease in the ventricular fibrillation occurrence from 100 % to 8 % (p < 0.001) after the administration of the 44Bu compound. In the B group, the onsets of all monitored arrhythmia types were delayed by an average of 15.6 min. Ventricular rhythm occurrence was decreased from 100 to 20 %, as well as ventricular fibrillations, from 100 to 0 % (p < 0.001).
Bartosová
Ladislava
L
Department of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences, 612 42 Brno, Czech Republic. bartosoval@vfu.cz
Novák
Filip
F
Frydrych
Marek
M
Parák
Tomás
T
Opatrilová
Radka
R
Brunclík
Vít
V
Kolevská
Jana
J
El Moataz
Elnaggar
E
Necas
Jirí
J
D000157:Aconitine / Q000633:toxicity*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy*; D001565:Benzoates / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001565:Benzoates; D000157:Aconitine